| | SAN DIEGO, April 7, 2021 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., Chief Executive Officer, will participate in virtual one-on-one meetings along with Denise Bevers, Chief Operating Officer, at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021. 
About DTx Pharma
DTx Pharma, Inc. is a privately-held biotechnology company based in San Diego, CA creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform toward and into clinical development, DTx has raised more than $100M in combined investment from several of the world’s leading healthcare investors including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma. Contact:
Company:
Denise Bevers
Chief Operating Officer
619-723-6476
dbevers@dtxpharma.com Media:
Amy Conrad
Juniper Point
858-366-3243
amy@juniper-point.com  View original content to download multimedia:http://www.prnewswire.com/news-releases/dtx-pharma-to-participate-in-the-2021-needham-virtual-healthcare-conference-301264077.html
SOURCE DTx Pharma | |
